Ruibin F. Huang
Nanchang, China
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 29 publications
Hetrombopag for patients with persistent primary immune thrombocytopenia: a post hoc analysis of a multicenter, randomized phase Ⅲ trial.
Journal: Research and practice in thrombosis and haemostasis
Published: July 03, 2025
Efficacy and safety analysis of China's first 10% IVIg (RonsenGlob) therapy in treating adult ITP.
Journal: Annals of hematology
Published: December 08, 2024
Safety and efficacy of luspatercept in treating anemia associated with myelodysplastic syndrome with ring sideroblasts in Asian patients who require red blood cell transfusions: a phase II bridging study.
Journal: Therapeutic advances in hematology
Published: August 12, 2024
Exosomal miR-146a-5p derived from bone marrow mesenchymal stromal cells regulate Th1/Th2 balance and alleviates immune thrombocytopenia in pregnancy.
Journal: Human cell
Published: July 05, 2024
Switching from eltrombopag to hetrombopag in patients with primary immune thrombocytopenia: a post-hoc analysis of a multicenter, randomized phase III trial.
Journal: Annals of hematology
Published: April 17, 2024
Efficacy and safety of sovleplenib (HMPL-523) in adult patients with chronic primary immune thrombocytopenia in China (ESLIM-01): a randomised, double-blind, placebo-controlled, phase 3 study.
Journal: The Lancet. Haematology
Published: April 02, 2024
A phase 2 trial of orelabrutinib showing promising efficacy and safety in patients with persistent or chronic primary immune thrombocytopenia.
Journal: American journal of hematology
Published: January 28, 2024
Zuberitamab, an innovative anti-CD20 monoclonal antibody, for patients with primary immune thrombocytopenia in China: a randomized, double-blind, placebo-controlled, phase 2 study.
Journal: The Lancet regional health. Western Pacific
Published: January 10, 2024
Efficacy and safety of QL0911 in adult patients with chronic primary immune thrombocytopenia: A multicenter, randomized, double-blind, placebo-controlled, phase III trial.
Journal: Journal of translational internal medicine
Published: December 22, 2023
Sovleplenib (HMPL-523), a novel Syk inhibitor, for patients with primary immune thrombocytopenia in China: a randomised, double-blind, placebo-controlled, phase 1b/2 study.
Journal: The Lancet. Haematology
Published: November 07, 2022
Last Updated: 09/26/2026